Does the addition of Recombinant Luteinising Hormone (recLH) (Luveris) to a regimen of Recombinant Follicle Stimulating Hormone (recFSH) (Gonal-F) and Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide) improve ovarian response and implantation rates in patients age >35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?

Submission date	Recruitment status  No longer recruiting	<ul><li>Prospectively registered</li></ul>	
14/02/2006		Protocol	
Registration date 14/02/2006	Overall study status Completed	Statistical analysis plan	
		[X] Results	
Last Edited	Condition category	Individual participant data	
10/06/2014	Urological and Genital Diseases		

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Prof R. Homburg

#### Contact details

VU University Medical Center
Department of Obstetrics and Gynaecology
Division of Reproductive Medicine
P.O. Box 7057
Amsterdam
Netherlands

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

**Secondary identifying numbers** NTR546; 03/159

# Study information

Scientific Title

## **Acronym**

Luveris study

## **Study objectives**

The hypothesis of this study is that the addition of recLH (Luveris) to a protocol of recFSH (Gonal-F) and GnRH antagonist (Cetrotide) will improve the pregnancy rates in women over the age of 35 years undergoing IVF/ET.

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Received from local medical ethics committee

# Study design

Multicentre randomised open label active controlled parallel group trial

# Primary study design

Interventional

# Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

# Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Subfertility

#### **Interventions**

Patients will receive a standard protocol of Gonal-F (follitropine; 225 IU/day) from cycle day 2-4 and Cetrotide (Cetrorelix; 0.25 mg/day) from day 6 of stimulation. They will be randomized on day 6 of stimulation to receive either Gonal-F and Luveris (150 IU/day) or continue with Gonal-F alone. In both cases, the dose of Gonal-F will remain unchanged. As in our standard treatment protocol, human choronic gonadotropin (hCG) (Pregnyl) will be given when at least 3 follicles reach 16 mm and ovum collection, embryo replacement and luteal support with vaginal progesterone will all be applied as in our routine IVF procedures.

## Intervention Type

Other

#### Phase

**Not Specified** 

### Primary outcome measure

- 1. Pregnancy rate/embryo transfer
- 2. Implantation rate (hCG measurement 15 days after ovum pick up)

## Secondary outcome measures

- 1. Number of follicles >15 mm on day hCG
- 2. Number of ova collected

## Overall study start date

01/01/2006

## Completion date

01/01/2010

# **Eligibility**

#### Key inclusion criteria

Age >35 years undergoing IVF or intracytoplasmic sperm injection (ICSI) for any indication

## Participant type(s)

Patient

### Age group

Adult

## Sex

Female

## Target number of participants

600

## Key exclusion criteria

Women with polycystic ovary syndrome (PCOS)

### Date of first enrolment

01/01/2006

#### Date of final enrolment

01/01/2010

# Locations

### Countries of recruitment

Netherlands

# Study participating centre VU University Medical Center

Amsterdam Netherlands 1007 MB

# Sponsor information

## Organisation

VU University Medical Centre (VUMC) (Netherlands)

## Sponsor details

Department of Obstetrics and Gynaecology, Division of Reproductive Medicine P.O. Box 7057 Amsterdam Netherlands 1007 MB

## Sponsor type

Hospital/treatment centre

#### **ROR**

https://ror.org/00q6h8f30

# Funder(s)

## Funder type

Research organisation

#### Funder Name

Gynaecology Research Foundation (Stichting Wetenschappelijk Onderzoek Gynaecologie [SWOG])

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2013		Yes	No